Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00453193
Status:
TERMINATED
Last Update Posted:
2012-08-07
First Post:
2007-03-26
Brief Title:
Alemtuzumab and Pentostatin In T-cell Neoplasms
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
A Phase II Study of Alemtuzumab and Pentostatin In T-Cell Neoplasms
Status:
TERMINATED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to learn if giving pentostatin with alemtuzumab can help to control T-cell malignancy The safety of this combination therapy will also be studied
Detailed Description:
Alemtuzumab is an antibody protein that is directed towards a marker molecule on the surface of both B- and T- lymphoid cells It is currently approved for use in treating patients with chronic lymphocytic leukemia and has been studied in treating patients with a number of T-cell malignancies Alemtuzumab has been found to be effective in these conditions Pentostatin is a drug that is approved for treating patients with hairy cell leukemia a B-cell malignancy Pentostatin has also been studied in a number of T-cell cancers and has been found to be effective The purpose of this study is to see whether combining these drugs will prove to be more effective
If you are found to be eligible to take part in this study you will receive pentostatin through a central venous catheter in your vein once a week for 4 weeks and then every 2 weeks until the achievement of best response A central venous catheter is a sterile flexible tube that will be placed into a large vein while you are under local anesthesia Your physician will explain this procedure to you in more detail and you will be required to sign a separate consent form for this procedure
Alemtuzumab will also be given through a vein catheter on Days 1 2 and 3 The dose of alemtuzumab that you receive will be increased each day for the first 3 days to make sure that you tolerate it It will then be given three times per week until you achieve the best response If you develop reactions to alemtuzumab when given through a vein you may receive it by injections of the same dose under the skin
During the treatment you will have blood about 2 tablespoons drawn once a week for the first 4 weeks for routine blood tests These blood tests will then be repeated every 2 to 4 weeks for the remainder of the study At the end of treatment a bone marrow examination will be repeated to document your response Also if you had a chest X-ray or CT scans these will be repeated to confirm your level of response
The maximum amount of time that alemtuzumab will be given is 3 months The maximum amount of time that pentostatin will be given is 6 months You may be able to receive the treatment will your local oncologists However you will have close follow-up at M D Anderson You will be taken off this treatment if the disease gets worse during treatment or if unacceptable side effects develop
You will be continued to be followed either directly or by telephone to evaluate your long-term response to treatment on this study
This is an investigational study Both alemtuzumab and pentostatin are commercially approved drugs that have been used to treat T-cell malignancies A total of 60 patients will take part in this study All will be enrolled at M D Anderson
This is an investigational study Both alemtuzumab and pentostatin are commercially approved drugs that have been used to treat T-cell malignancies A total of 60 patients will take part in this study All will be enrolled at M D Anderson
If you are found to be eligible to take part in this study you will receive pentostatin through a central venous catheter in your vein once a week for 4 weeks and then every 2 weeks until the achievement of best response A central venous catheter is a sterile flexible tube that will be placed into a large vein while you are under local anesthesia Your physician will explain this procedure to you in more detail and you will be required to sign a separate consent form for this procedure
Alemtuzumab will also be given through a vein catheter on Days 1 2 and 3 The dose of alemtuzumab that you receive will be increased each day for the first 3 days to make sure that you tolerate it It will then be given three times per week until you achieve the best response If you develop reactions to alemtuzumab when given through a vein you may receive it by injections of the same dose under the skin
During the treatment you will have blood about 2 tablespoons drawn once a week for the first 4 weeks for routine blood tests These blood tests will then be repeated every 2 to 4 weeks for the remainder of the study At the end of treatment a bone marrow examination will be repeated to document your response Also if you had a chest X-ray or CT scans these will be repeated to confirm your level of response
The maximum amount of time that alemtuzumab will be given is 3 months The maximum amount of time that pentostatin will be given is 6 months You may be able to receive the treatment will your local oncologists However you will have close follow-up at M D Anderson You will be taken off this treatment if the disease gets worse during treatment or if unacceptable side effects develop
You will be continued to be followed either directly or by telephone to evaluate your long-term response to treatment on this study
This is an investigational study Both alemtuzumab and pentostatin are commercially approved drugs that have been used to treat T-cell malignancies A total of 60 patients will take part in this study All will be enrolled at M D Anderson
This is an investigational study Both alemtuzumab and pentostatin are commercially approved drugs that have been used to treat T-cell malignancies A total of 60 patients will take part in this study All will be enrolled at M D Anderson
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None